Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 7/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26209173 | 0.86 | ITGB3 (0.41) | CHRM3L3MBTL1GLP1RCYP3A4CYP2D6 | |
| SCHEMBL26997769 | 0.86 | CHRM3 (0.37) | CHRM3L3MBTL1GLP1RCYP3A4CYP2D6 | |
| SCHEMBL29108917 | 0.82 | CHRM3 (0.43) | CHRM3L3MBTL1SMN1; SMN2GLP1RCYP3A4 | |
| SCHEMBL26207994 | 0.82 | CHRM3 (0.43) | CHRM3L3MBTL1SMN1; SMN2GLP1RCYP3A4 | |
| SCHEMBL15781609 | 0.81 | EPHX2 (0.40) | CHRM3EPHX2SMN1; SMN2HRH3 | |
| SCHEMBL26728754 | 0.79 | XPNPEP1 (0.36) | CHRM3L3MBTL1SMN1; SMN2GLP1RCA12 | |
| SCHEMBL15782960 | 0.79 | SMN1; SMN2 (0.41) | EPHX2L3MBTL1SMN1; SMN2HRH3HTT | |
| SCHEMBL26208211 | 0.78 | CHRM3 (0.43) | CHRM3EPHX2L3MBTL1SMN1; SMN2HRH3 | |
| SCHEMBL26209206 | 0.77 | CHRM3 (0.38) | CHRM3EPHX2L3MBTL1SMN1; SMN2HRH3 | |
| SCHEMBL26999994 | 0.76 | MEN1 (0.45) | CHRM3EPHX2L3MBTL1SMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CHRM3 179/4885EPHX2 3576/4885L3MBTL1 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.